Emergence of a novel hybrid \textit{mcr-1}-bearing plasmid in an NDM-7-producing ST167 \textit{Escherichia coli} strain of clinical origin

Shuang Xia\textsuperscript{1}, Wei Wang\textsuperscript{1}†, Jing Cheng\textsuperscript{2,3}, Tingting Zhang\textsuperscript{2,3}, Ziwei Xia\textsuperscript{2,3}, Xiaoyu Zhao\textsuperscript{2,3}, Yungang Han\textsuperscript{1}, Yonghong Li\textsuperscript{2,3}*, Xiufang Shi\textsuperscript{2,3}* and Shangshang Qin\textsuperscript{2,3}*

\textsuperscript{1}Department of Medical Laboratory, Henan Provincial Chest Hospital, Zhengzhou, China, \textsuperscript{2}School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, China, \textsuperscript{3}Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education, Zhengzhou University, Zhengzhou, China

Colistin is considered as an antibiotic of ‘last resort’ for the treatment of lethal infections caused by carbapenem-resistant \textit{Enterobacterales} (CRE), dissemination of plasmid-borne colistin resistance gene \textit{mcr-1}, particularly into CRE, resulting in the emergence of strains that approach pan-resistance. A wide variety of plasmid types have been reported for carrying \textit{mcr-1}. Among which, large IncHI2-type plasmids were multidrug-resistant (MDR) plasmids harbored multiple resistance determinants in addition to \textit{mcr-1}. Herein, we characterized a novel hybrid IncHI2-like \textit{mcr-1}-bearing plasmid in an \textit{NDM-7}-producing \textit{ST167 Escherichia coli} strain from clinical origin.

Antimicrobial susceptibility testing showed \textit{E. coli} EC15-50 exhibited an extensively drug-resistant (XDR) profile that only susceptible to amikacin and tigecycline. S1-PFGE, Southern hybridization and Whole-genome Sequencing (WGS) analysis identified a 46,161 bp \textit{bla\textit{NDM-7}}-harboring IncX3 plasmid pEC50-NDM7 and a 350,179 bp \textit{mcr-1}-bearing IncHI2/HI2A/N/FII/FIA plasmid pEC15-MCR-50 in \textit{E. coli} EC15-50. Sequence detail analysis revealed the type IV coupling protein (T4CP) gene was absent on pEC15-MCR-50, explaining that pEC15-MCR-50 was a non-conjugative plasmid. Comparative genetic analysis indicated the hybrid plasmid pEC15-MCR-50 was probably originated from pXGE1\textit{mcr-1}-like IncHI2/IIA/N plasmid and pSJ94-94-like IncFII/FIA plasmid, and generated as a result of a replicative transposition process mediated by IS26. Currently, the prevalent \textit{mcr-1}-carrying IncHI2 plasmids were rarely reported to be fused with other plasmids. The identification of the novel hybrid plasmid pEC15-MCR-50 in this study highlighted the importance of close surveillance for the emergence and dissemination of such fusion MDR plasmids, particularly in NDM-producing \textit{Enterobacterales}.

**KEYWORDS**

\textit{Escherichia coli}, ST167, \textit{mcr-1}, cointegrate plasmid, \textit{Is\textit{26}}
Introduction

Carbapenem-resistant *Enterobacterales* (CRE) strains, which exhibited multi-drug resistant or extensively drug resistant patterns and were associated with high mortality rates, were regarded as a serious threat for public health (CPS, 2019). Given that less effective treatment options left for treating infections caused by CRE, colistin that belongs to cationic antimicrobial peptides with neurotoxic effects has been used as a last resort of antibiotic against CRE in clinic. Unfortunately, emergence and global dissemination of plasmid-borne colistin resistance gene *mcr-1* that encodes phosphoethanolamine transferase among *Enterobacterales*, especially in CRE, led to the emergence of potentially untreatable strains.

Since the first mobile colistin resistance (*mcr*) gene, *mcr-1*, was identified in *Escherichia coli* in 2016 from China, more *mcr* variants (*mcr-1* to *mcr-10*) were reported in different species of *Enterobacterales* exhibiting MDR phenotypes isolated from animals, food samples and clinical settings origin worldwide, and *mcr-1* was the most frequently detected and globally spread variant (Wang *et al.*, 2018, 2020). Various *mcr-1*-encoding plasmids belonging to IncI2, IncX4, IncP, IncY, IncFII, IncN, IncQ and IncHI2 incompatibility groups have been described as the vector facilitates the dissemination of *mcr-1* (Ye *et al.*, 2016; Wang *et al.*, 2018). Among which, IncI2, IncHI2 and IncX4 were the most common plasmid types (Wu *et al.*, 2018; Matamoros *et al.*, 2020). Unlike these two types of small plasmids (IncI2: ~65 kb, IncX4: ~33 kb) that only carried a single resistance gene *mcr-1*, IncHI2 type plasmids with large size (> 200 kb) always harbored multiple resistance determinants beside *mcr-1* (Tang *et al.*, 2020). In addition, hybrid *mcr-1*-bearing plasmids have also been described, such as pCQ02-121, a transferable IncX3/X4 hybrid plasmid co-harboring *mcr-1* and *blaNDM-5* (Sun *et al.*, 2016). Recently, the generation of hybrid and cointegrate *mcr-1* plasmids mediated by IS26 or ISCR2 were found in the process of conjugation (He *et al.*, 2019; Li *et al.*, 2020), promoting the dissemination of resistance genes and extending the resistance profile and the host spectrum for the fusion plasmid, which poses an enormous threat to public health.

Herein, we characterized a hybrid *mcr-1*-bearing plasmid containing IncFII, IncFIA, IncH12, IncH12A and IncN replicons in an ND-M-7-producing extensively drug resistant (XDR) ST167 *E. coli* clinical isolate. Based on its structural features, we proposed a putative IS26-mediated formation model of this novel IncH12/H12A/N/FII/FIA hybrid plasmid.

Materials and methods

**Bacterial isolation, antimicrobial susceptibility testing and PCR detection**

*Escherichia coli* EC15-50 was obtained from the sputum culture of a 44-year-old male patient hospitalized in respiratory intensive care unit (RICU) at a tertiary hospital in Zhengzhou city in 2015. This isolate was identified by using the Vitek 2 system (bioMérieux, France) and 16S rDNA gene sequencing. Antimicrobial susceptibility testing was determined by using the broth microdilution method and agar dilution method (for fosfomycin) according to the Clinical and Laboratory Standards Institute guidelines (CLSI, 2020) and the European Committee on Antimicrobial Susceptibility Testing (EUCAST).1 *E. coli* ATCC25922 was used as the quality-control strain. PCR was used to detect the presence of the colistin resistance gene *mcr* and carbapenemase-encoding genes, including *blaNDM-5*, *blaOXA*, *blaKPC*, *blaVIM*, and *blaIMP* with primers described previously (Qin *et al.*, 2014).

**S1-PFGE and Southern blotting**

To detect the location of the *blaNDM-5* and *mcr-1* gene, whole-cell genomic DNA of the *E. coli* EC15-50 isolate was digested by S1 nuclease (TaKaRa, Dalian, China) in agarose gel plug and then separated by pulsed-field gel electrophoresis (PFGE) under the conditions reported previously (Qin *et al.*, 2014). The location of the *blaNDM-5* and *mcr-1* gene was indicated by Southern hybridization using a digoxigenin-labeled *blaNDM-5* and *mcr-1* gene fragment probe, respectively, using a DIG-High Prime DNA Labeling and Detection Starter Kit II (Roche Diagnostics, Basel, Switzerland) according to the manufacturer’s instructions.

**Whole-genome sequencing (WGS) and bioinformatics analysis**

Whole-genome DNA of *E. coli* EC15-50 was extracted with the Wizard genomic DNA purification kit (Promega, Madison, WI, United States) and then sequenced using the Illumina MiSeq platform (San Diego, CA, United States) and the Pacific Biosciences RS II platform (Pacific Biosciences, Menlo Park, CA, United States). Sequencing reads were assembled into scaffolds using GS De Novo Assembler software (version 3.0). The prediction and annotation of ORFs were performed using Glimmer 3.02.7 Antimicrobial resistance genes (ARGs) were identified by using Resfinder (Bortolaia *et al.*, 2020). Plasmid identified in this study was analyzed using PlasmidFinder2 and pMLST4 to investigate the replicons (Carattoli *et al.*, 2014). Sequence alignments for the genetic environments of *mcr-1* were performed using BLAST.1
TABLE 1 Antimicrobial susceptibilities of strain Escherichia coli EC15-50.

| Antimicrobial category              | Antimicrobial agents | MIC* (μg/mL) | EC15-50 |
|------------------------------------|----------------------|--------------|---------|
| Penicillins                        | Ampicillin           | >256         |         |
| Penicillins+β-lactamase inhibitors | Ampicillin/sulbactam | >256         |         |
| Antipseudomonal                    |                      |              |         |
| Penicillins+β-lactamase inhibitors | Piperacillin/tazobactam | >256       |         |
| Non-extended spectrum cephalosporins | Cefazolin           | >256         |         |
| Extended spectrum                  |                      |              |         |
| Cephalosporins                     | Ceftazidime          | >32          |         |
|                                    | Cefepime             | >256         |         |
| Carbapenems                        | Imipenem             | >32          |         |
|                                    | Meropenem            | >32          |         |
| Monobactams                        | Aztreonam            | >32          |         |
| Other antimicrobials               |                      |              |         |
| Fluoroquinolones                   | Ciprofloxacin        | 32           |         |
| Aminoglycosides                    | Gentamicin           | 32           |         |
| Phenicol                          | Amikacin             | ≤2           |         |
| Phosphonic acids                   | Chloramphenicol      | >32          |         |
| Tetracyclines                      | Doxycycline          | >32          |         |
| Glycylcyclines                     | Tigecycline          | ≤0.5         |         |
| Polymyxins                         | Colistin             | 4            |         |

*MIC, minimum inhibitory concentration.

Results and discussion

Characteristics of Escherichia coli EC15-50 co-harboring blaNDM-7 and mcr-1

Clinical strain E. coli EC15-50 belonging to ST167 was recovered from the sputum culture of a 44-year-old male patient with acute lymphoblastic leukemia in 2015. In vitro antimicrobial susceptibility testing results showed that strain EC15-50 exhibited extensively drug resistant (XDR) profile for a wide range of antimicrobial agents, resistant to all cephalosporins, carbapenems, β-lactam/β-lactamase inhibitors, fluoroquinolones, gentamicin, chloramphenicol, fosfomycin and doxycycline as well as colistin, but susceptible to amikacin and tigecycline (Table 1). PCR and sequencing based on carbapenems and colistin resistance profiles revealed the co-occurrence of blaNDM-7 and mcr-1 gene in EC15-50. S1-PFGE and hybridization results further indicated the blaNDM-7 and mcr-1 gene were located on separated plasmids with the sizes of ~45 kb and ~350 kb, respectively (Figure 1).

E. coli has been regarded as the predominant species in Enterobacterales for carrying blaNDM, as well as mcr-1 gene, and co-occurrence of blaNDM and mcr was most frequently detected in E. coli strains (Han et al., 2020). Among these blandaNDM and mcr positive strains, blandaNDM and mcr-1 were the most common reported variants combination. However, the blandaNDM and mcr-1 gene co-harbor E. coli have not been described. Our study represented the first report of clinical E. coli strain co-producing NDM-7 and MCR-1 that belongs to sequence type ST167. Notably, E. coli ST167 is classified as an internationally disseminated clonal lineage associated with the global spread of blaCTX-M-15 and blandaNDM genes. It has been considered as high-risk clone and is emerging associated with β-lactamases mainly in clinical samples origin throughout the world (Sánchez-Beníto et al., 2017; Nukui et al., 2019; Xu et al., 2019). Dissemination of mcr-1 within the successful epidemic clone may facilitate further spread of colistin resistance in β-lactamases-producing E. coli isolates.

Conjugation experiments

Conjugation assays were performed to assess the transferability of mcr-1 gene according to the method described previously with minor modification (Wang et al., 2019). Briefly, approximately 1 x 10⁶ colony-forming units (CFU)/mL of the donor strain (EC15-50) and the rifampicin-resistant E. coli isolate EC600 as the recipient strain were mixed at a ratio of 1:4 on LB agar and cultured for 12 h. The mixture were collected and then plated on an LB agar containing rifampicin (64 μg/ml) and colistin (1 μg/ml). All suspected transconjugants were verified by PCR amplification for mcr-1, and antimicrobial susceptibility testing.

Plasmid stability testing

The stability of plasmid pEC15-MCR-50 was studied by passage in antibiotic-free Luria broth (LB) as previously described with minor modification (Sandegren et al., 2012). Briefly, the plasmid-containing E. coli EC15-50 were grown in 1 ml LB broth at 37°C for 12 h. The bacterial cells cultured for 12 h were washed by centrifugation and resuspended in 1 ml LB broth. Transfer 1 μl washed cells into 1 ml LB broth and incubate at 37°C for 12 h. For continuous culture, wash 1 μl cells into 1 ml LB broth once every 12 h, approximately 10 generations of growth per passage, for 10 consecutive days. The 200 generation strains were diluted and spread on LB agar plates. Then, 50 colonies were screened on LB agar plates supplemented with 2 μg/ml colistin, and the stability and integrity of the plasmid pEC15-MCR-50 carrying mcr-1 gene across passages were investigated by PCR mapping technology. PCR primers were summarized in Supplementary Table S1.

Plasmid stability testing

The stability of plasmid pEC15-MCR-50 was studied by passage in antibiotic-free Luria broth (LB) as previously described with minor modification (Sandegren et al., 2012). Briefly, the plasmid-containing E. coli EC15-50 were grown in 1 ml LB broth at 37°C for 12 h. The bacterial cells cultured for 12 h were washed by centrifugation and resuspended in 1 ml LB broth. Transfer 1 μl washed cells into 1 ml LB broth and incubate at 37°C for 12 h. For continuous culture, wash 1 μl cells into 1 ml LB broth once every 12 h, approximately 10 generations of growth per passage, for 10 consecutive days. The 200 generation strains were diluted and spread on LB agar plates. Then, 50 colonies were screened on LB agar plates supplemented with 2 μg/ml colistin, and the stability and integrity of the plasmid pEC15-MCR-50 carrying mcr-1 gene across passages were investigated by PCR mapping technology. PCR primers were summarized in Supplementary Table S1.
Identification of a novel hybrid mcr-1-bearing plasmid pEC15-MCR-50

Sequence analysis showed that the 46,161 bp blaNDM-7-harboring plasmid pEC50-NDM7 (KX470735), which was nearly identical to a reported plasmid pKpN01-NDM7 (CP012990) with a single nucleotide change from A to G at 31,701 bp, was a typical IncX3 plasmid carrying only one resistance gene blaNDM-7. However, the mcr-1-bearing plasmid pEC15-MCR-50 (MG656414), with a length of 350,179 bp and an average GC content of 48.0%, was a hybrid plasmid containing multiple replicons including IncFII, IncFIA, IncHI2, IncHI2A and IncN. ResFinder analysis identified a number of antimicrobial resistance genes in pEC15-MCR-50, including aminoglycosides resistance genes aac(3)-IV, aph(3’)-Ia, aph(4)-Ia, aadA1 and aadA2b, macrolides resistance gene mph(A), β-lactamases resistance gene blaCTX-M-14, phenicols resistance genes cmlA1 and floR, tetracyclines resistance gene tetr(C), fosfomycin resistance gene fosA3, sulfonamides resistance genes sul2 and sul3 in addition to colistin resistance gene mcr-1 (Figure 2A). Interestingly, these resistance genes were distributed in three distinct regions of pEC15-MCR-50, a 3,673 bp mcr-1-containing cassette ISApl1-mcr-1-pap2 and a 6,867 bp mph(A)-harboring segment organized as IS15DI-repB(N)-IS5075-IS26-mph(A) were located in the backbone. However, the remaining resistance genes which were dispersed between multiple insertion sequences were located in the variable region. Additionally, genes responsible for plasmid maintenance including parB, sopA (plasmid partition) and ccdAB (toxin-antitoxin system) and conjugation and transfer (tra-relative genes) were also observed in the backbone.

Plasmid pEC15-MCR-50 failed to transfer from the donor strain E. coli EC15-50 to the recipient isolate E. coli EC600 in the conjugation assay. Sequence analysis by oriTfinder identified the oriT region, relaxase gene and T4SS gene cluster on plasmid pEC15-MCR-50, but the type IV coupling protein (T4CP) gene was absent. Given that the four components are necessary for conjugation in self-transmissible plasmids (Smillie et al., 2010), incomplete MOB module might be responsible for the non-conjugative profile of pEC15-MCR-50.

Proposed formation mechanism of the plasmid pEC15-MCR-50

Based on the detailed sequence analysis of pEC15-MCR-50, we found it was a cointegrate plasmid with chimeric characteristics consisting of a ~243-kb pXGE1mcr (KY990877) -derived module (Module C) and a ~107-kb pSJ_94 (CP011064) -derived module (Module D; Figure 2A). Comparative genomic analysis between the hypothetical ancestor plasmid pXGE1mcr and the Module C sequence indicated that formation of this module was due to a series of genetic events. It is proposed that the deletion of a 12,747 bp of IS26-orf1-hipA-orf2 in pXGE1mcr formed Module A. Subsequently, the genetic rearrangement of a 9,379 bp fragment organized as IS6100-orf3-IS15DI-repB(N)-IS5075-IS26-mph(A) immediately upstream of the tnpA gene and downstream of the tnpR gene, causing the insertion of macrolide resistance determinant containing part IS15DI-repB(N)-IS5075-IS26-mph(A) in the backbone region and the integration of the remnant part of the 2,512 bp fragment between the tnpA gene and the IS15DI, resulting in the formation of Module B. Finally, insertion of the IS26-tet(M)-orf4-tnp-IS5075 element, conferring resistance to tetracyclines, as previously described in pHS13-1-IncHI2.

6 https://tool-mml.sjtu.edu.cn/oriTfinder/oriTfinder.html
(Liu et al., 2020a), upstream of the orf3 gene in Module B formed Module C. On the other hand, Module D was proposed formation from an IncFIA/FII plasmid pSJ_94 (CP011064) by insertion of Tn5403 (tnpR-tnpA-orf5) downstream of repA1 flanked by a 3 bp direct repeat (GCC) and a 1,005 bp of IS5075 upstream of the tnp gene at the end of the sequence flanked by a 2 bp direct repeat (AA), respectively.

The observed presence of an 8bp direct repeat (AAAAATTCC) bracketed the Module D segment indicated cointegrate formation is much more likely to be mediated by IS26 element. Close inspection of the overall structure of pEC15-MCR-50, we proposed a possible model of cointegrate formation indicated by Figure 2B. In this model, IS26 in Module D attacked the target site 0 (AAAAATTCC) in
**mcr-1**-harbored Module C and then replicative cointegrate formation occurred. Module D was incorporated into the downstream of IS6100 in Module C creating the cointegrate pEC15-MCR-50 and resulting in an 8bp target site duplications (TSD) and acquisition of an additional copy of IS26. Eventually, two direct repeats of the TSDs were present surrounding Module D.

IS26 was regarded as a vital mobile element contributed to the dissemination and rearrangement of resistance determinants, as well as plasmid reorganization (Harmer and Hall, 2015; He et al., 2015; Wei et al., 2022). A previous study demonstrated that IS26 was involved in recombination of an IncN1-F33: A-: B- plasmid and an **mcr-1**-carrying phage-like plasmid during conjugation process, facilitating the dissemination of **mcr-1** (He et al., 2019). Additionally, IS26 was also reported to play an important role in generation of blaoxy- and blaqpen- bearing MDR cointegrate plasmids. A 59kb cointegrate plasmid PT18 (CP017086) from *Proteus mirabilis* was likely to be generated by IS26-mediated cointegrate formation between the IncN-type plasmid pT211 (containing blaOXY-2) and the IncFII-33 plasmid (blaTEM-1B, blaqCTX-M-15, rmtB and fosA3; Hua et al., 2020), and a 122kb plasmid pLS3T in the transconjugant of *E. coli* L53 was formed due to IS26-mediated fusion of pL53-4 (CP034737), a typical blaoxy- bearing IncX3 plasmid, and pL53-3 (CP034736), an IncFII-type plasmid harboring fosA, blaqCTX-M-53 and blaqTEM-1b during the conjugation process (Liu et al., 2020b). IS26-mediated plasmid recombination can not only lead to the emergence of large-size MDR plasmids but also accelerate the evolution of virulence plasmids. The entire *Salmonella Enteritidis*-specific virulence plasmid pSEN (HG970000) was observed to fuse with another IncHI2 MDR plasmid (KX518743) mediated by IS26 to generate a cointegrate virulence-resistance plasmid pSE380T (KY401053; Wong et al., 2017). Similar to pSE380T, the 244kb plasmid pCR-HvKP3TC-2_Vir-p3 (OM001475) was also found to be a fusion plasmid generated by IS26-mediated recombination of virulence plasmid pVir-CR-HvKP3 (MW598234) and plasmid p3-CR-HvKP3 (MW598238; Yang et al., 2022).

In addition to IS26, ISCR2 has also been reported to reorganize the **mcr-1**-bearing large plasmid and was responsible for **mcr-1**-bearing large fused MDR plasmids (Li et al., 2020). Compared with previous reported IS26-mediated N1-F33: A-: B- **mcr-1**-bearing hybrid plasmid (MK419512), the H2/H12A/N/FII/FIA type plasmid pEC15-MCR-50 which possibly generated as a result of a replicative transposition process mediated by IS26, was identified as an MDR plasmid, carrying more resistance determinants. Although this plasmid could not be transferred by conjugation, it remained stable in strain in antimicrobial agent-free environment and could be served as a reservoir of multiple resistance genes. Based on the important role of IS26 in mediating plasmid reorganization, further attention should be paid to focusing on this element in hybrid plasmids to trace the evolution of MDR or virulence plasmids.

### The stability of the plasmid pEC15-MCR-50

The serial passages and PCR mapping results showed that the plasmid pEC15-MCR-50 from *E. coli* EC15-50 could be retained at 100% over 200 generations of passage, revealing that the large fusion plasmid pEC15-MCR-50 remained stable in antimicrobial agent-free environment, and the resistance genes in this novel hybrid plasmid can be stably inherited.

### Conclusion

Polymyxin is regarded as the last line of defense in the clinical treatment of CRE infections. Emergence of **mcr-1** in NDM-producing *Enterobacteriales* can seriously limit clinical treatment options. Our study identified and characterized an **mcr-1**-bearing IncHI2/HI2A/N/FII/FIA hybrid plasmid in NDM-7-producing XDR ST167-type *E. coli* of clinical origin. Detail analysis showed that IS26 might be responsible for this **mcr-1**-bearing large fused plasmid. The formation of fusion plasmid was likely to maintain the stability of **mcr-1** gene, which may facilitate bacteria to adapt to the antibiotic stress. Close surveillance is urgently needed to monitor the emergence and dissemination of *E. coli* co-producing NDM and MCR-1, as well as such fusion MDR plasmids.

### Data availability statement

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found at: NCBI – KX470735, MG656414.

### Author contributions

SQ, XS, and YL designed the study. SX, WW, JC, and YH performed the experiments. TZ, JC, ZX, and XZ analyzed the bioinformatics data. SQ and JC wrote the manuscript. All authors contributed to the article and approved the submitted version.

### Funding

This work was supported by grant U2004125 from the National Natural Science Foundation of China (SQ), the Key R&D and Promotion Project of Henan Province (No. 212102310246, 2018010038) of China.
Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmicb.2022.950087/full#supplementary-material